Deep Heat Litwa - litewski - SMCA (Valstybinė vaistų kontrolės tarnyba)

deep heat

the mentholatum company (ireland) limited - metilsalicilatas/levomentolis ir raceminis mentolis/eukaliptų (eucalyptus) eterinis aliejus/terpentino eterinis aliejus - kremas - 128 mg/59,1 mg/19,7 mg/14,7 mg/g - various

Deep Relief Litwa - litewski - SMCA (Valstybinė vaistų kontrolės tarnyba)

deep relief

the mentholatum company (ireland) limited - ibuprofenas/levomentolis - gelis - 50 mg/30 mg/g - various

SmofKabiven Peripheral Litwa - litewski - SMCA (Valstybinė vaistų kontrolės tarnyba)

smofkabiven peripheral

fresenius kabi ab - gliukozė, monohidratas/alaninas/argininas/glicinas/histidinas/izoleucinas/leucinas/lizino acetatas/metioninas/fenilalaninas/prolinas/serinas/taurinas/treoninas/triptofanas/tirozinas/valinas/kalcio chloridas dihidratas/natrio glicerofosfatas hidratas/magnio sulfatas heptahidratas/kalio chloridas/natrio acetatas trihidratas/cinko sulfatas heptahidratas/sojų aliejus, rafinuotas/trigliceridai, vidutinės grandinės/alyvuogių aliejus, rafinuotas/Žuvų taukai, praturtinti omega-3 rūgštimis - infuzinė emulsija - 71 g/4,4 g/3,8 g/3,5 g/0,93 g/1,6 g/2,3 g/2,1 g/1,3 g/1,6 g/3,5 g/2,1 g/0,32 g/1,4 g/0,63 g/0,12 g/2 g/0,18 g/1,3 g/0,38 g/1,4 g/1,1 g/0,004 g/8,5 g/8,5 g/7 g/4,2 g/1000 ml; 71 g/4,4 g/3,8 g/3,5 g/0,93 g/1,6 g/2,3 g/2,1 g/1,3 g/1,6 g/3,5 g/2,1 g/0,32 g/1,4 g/0,63 g/0,12 g/2 g/0,18 g/1,3 g/0,38 g/1,4 g - combinations

Kabiven Peripheral Litwa - litewski - SMCA (Valstybinė vaistų kontrolės tarnyba)

kabiven peripheral

fresenius kabi ab - išgrynintas sojų aliejus/gliukozė/alaninas/argininas/asparto rūgštis/glutamo rūgštis/glicinas/histidinas/izoleucinas/leucinas/lizinas/metioninas/fenilalaninas/prolinas/serinas/treoninas/triptofanas/tirozinas/valinas/kalcio chloridas/natrio glicerofosfatas/magnio sulfatas/kalio chloridas/natrio acetatas - infuzinė emulsija - 51 g/97 g/4,8 g/3,4 g/1 g/1,7 g/2,4 g/2 g/1,7 g/2,4 g/2,7 g/1,7 g/2,4 g/2 g/1,4 g/1,7 g/0,57 g/0,069 g/2,2 g/0,22 g/1,5 g/0,48 g/1,8 g/1,5 g/1440 ml; 51 g/97 g/4,8 g/3,4 g/1 g/1,7 g/2,4 g/2 g/1,7 g/2,4 g/2,7 g/1,7 g/2,4 g/2 g/1,4 g/1,7 g/0,57 g/0,069 g/2,2 g/0,22 g/1,5 g/0,48 g - combinations

Onpattro Unia Europejska - litewski - EMA (European Medicines Agency)

onpattro

alnylam netherlands b.v. - patisiran natrio - amiloidozė, Šeimyniniai - kiti nervų sistemos vaistai - onpattro fluorouracilu gydyti paveldimų transthyretin tarpininkaujant amiloidozė (hattr amiloidozė) suaugusiems pacientams, sergantiems 1 ir 2 etapų polyneuropathy.

GHRYVELIN (previously Macimorelin Aeterna Zentaris) Unia Europejska - litewski - EMA (European Medicines Agency)

ghryvelin (previously macimorelin aeterna zentaris)

atnahs pharma netherlands b.v. - macimorelin acetatas - diagnostikos metodus, endokrininės sistemos - macimorelin - Šis vaistas yra skirtas tik diagnostikai.  ghryvelin is indicated for the diagnosis of growth hormone deficiency (ghd) in adults.

Stelfonta Unia Europejska - litewski - EMA (European Medicines Agency)

stelfonta

qbiotics netherlands b.v. - tigilanol tiglate - tigilanol tiglate - Šunys - gydyti ne resectable, ne metastazavusio (kurie sustojimo) poodinio putliųjų ląstelių navikai įsikūręs, ar distalinės į alkūnės arba kulno, ir ne resectable, neišplitusia odos putliųjų ląstelių navikų šunys.

Ayvakyt Unia Europejska - litewski - EMA (European Medicines Agency)

ayvakyt

blueprint medicines (netherlands) b.v. - avapritinib - virškinimo trakto stromos navikai - kiti antinavikiniai vaistai agentai, baltymų kinazės inhibitoriai - ayvakyt is indicated as monotherapy for the treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumours (gist) harbouring the platelet-derived growth factor receptor alpha (pdgfra) d842v mutation.

Comirnaty Unia Europejska - litewski - EMA (European Medicines Agency)

comirnaty

biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vakcinos - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. naudoti šios vakcinos turėtų būti laikantis oficialių rekomendacijų.

Tecartus Unia Europejska - litewski - EMA (European Medicines Agency)

tecartus

kite pharma eu b.v. - autologous peripheral blood t cells cd4 and cd8 selected and cd3 and cd28 activated transduced with retroviral vector expressing anti-cd19 cd28/cd3-zeta chimeric antigen receptor and cultured (brexucabtagene autoleucel) - limfoma, mantle-cell - antinavikiniai vaistai - mantle cell lymphomatecartus is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl) after two or more lines of systemic therapy including a bruton’s tyrosine kinase (btk) inhibitor. acute lymphoblastic leukaemiatecartus is indicated for the treatment of adult patients 26 years of age and above with relapsed or refractory b-cell precursor acute lymphoblastic leukaemia (all).